<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256073</url>
  </required_header>
  <id_info>
    <org_study_id>IPH 2101-102</org_study_id>
    <nct_id>NCT01256073</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia</brief_title>
  <official_title>An Open-label, Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a multi-centre, open-label, safety and tolerability extension trial to the&#xD;
      IPH2101-101 (previously NN1975-1733) first human dose trial completed with a larger subject&#xD;
      pool at an optimal dose level. The trial is conducted in elderly Acute Myeloid Leukemia (AML)&#xD;
      patients over the age of 60 years, in complete remission, and who are not eligible for&#xD;
      allogeneic stem-cell transplantation. The dose given to the individual patient will be the&#xD;
      same as the patient received in the single dose trial IPH2101-101 and 1 mg/kg or 2 mg/kg for&#xD;
      the 12 patients in an additional cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety and tolerability of repeating dosings of Anti-KIR(1-7F9)</measure>
    <time_frame>every 2 weeks</time_frame>
    <description>using the US National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetics upon repeated dosing(s)of Anti-KIR(1-7F9)</measure>
    <time_frame>every 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacodynamics upon repeated dosing(s) of Anti-KIR(1-7F9)</measure>
    <time_frame>every 2 or 4 weeks</time_frame>
    <description>Degree of KIR-occupancy on patient NK-cells&#xD;
Plasma inflammatory cytokines (IFN-γ, TNF-α, IL-1, IL-6)&#xD;
Immunophenotyping (NK-, B- and T-lymphocyte counts and activation status)&#xD;
NK-cell surface markers (activation markers and inhibitory receptors)&#xD;
Functional assay of NK-cell activity only for patient from additional cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess signs of efficacy of repeated dosing(s) with Anti-KIR(1-7F9)</measure>
    <time_frame>to date of progression diagnosed or until death</time_frame>
    <description>Reduction in minimal residual disease measured by WT-1 expression in blood and bone marrow&#xD;
Progression-free survival (measured as calendar days from the first dosing of Anti-KIR(1-7F9) (in the IPH2101-101 trial) to date of progression diagnosed or until death by any cause&#xD;
Overall survival measured as calendar days from the first dosing of Anti-KIR (1-7F9) to date of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>IPH2101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPH2101</intervention_name>
    <description>IPH2101 fully human anti-KIR monoclonal antibody</description>
    <arm_group_label>IPH2101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent obtained before any trial-related activities (Trial-related&#xD;
             activities are any procedure that would not have been performed during normal&#xD;
             management of the subject)&#xD;
&#xD;
          2. Acute myeloid leukaemia (AML) according to WHO Criteria&#xD;
&#xD;
          3. Morphological complete remission (CR) defined according to NCI criteria, or CRi with&#xD;
             incomplete platelet count recovery only after 1 or 2 cycles of induction chemotherapy,&#xD;
             and at least 1, and maximally 6 cycles of consolidation chemotherapy:&#xD;
&#xD;
               -  Absolute neutrophile count &gt; 1x 109/L&#xD;
&#xD;
               -  Platelets &gt; 80x109/L&#xD;
&#xD;
               -  Independency of blood transfusions&#xD;
&#xD;
               -  Less than 5% blasts in bone-marrow&#xD;
&#xD;
               -  No Auer rods&#xD;
&#xD;
               -  No symptoms of disease&#xD;
&#xD;
          4. Life expectancy &gt; 4 months as judged by the Investigator&#xD;
&#xD;
          5. The patient is &gt; or = 60 years of age but &lt; or = 80 years of age&#xD;
&#xD;
          6. The patient has completed participation in the IPH2101-101(previously&#xD;
             NN1975-1733)trial with an acceptable safety profile, as judged by the Investigator or&#xD;
             is screened for the additional cohort&#xD;
&#xD;
          7. Time since last dose of chemotherapy at least 30 days and no more than 60 days if the&#xD;
             patient did not participate in IPH2101-101 trial before&#xD;
&#xD;
          8. Recovery from acute toxicities of all previous anti-leukaemic therapies&#xD;
&#xD;
          9. KIR-expression on patient NK-cells (ability to bind Anti-KIR(1-7F9)) if the patient&#xD;
             did not participate in IPH2101-101 trial before&#xD;
&#xD;
         10. ECOG performance status 0, 1 or 2&#xD;
&#xD;
         11. No major organ dysfunction as judged by the Investigator&#xD;
&#xD;
         12. The patients must have the following clinical laboratory values:&#xD;
&#xD;
               -  Serum creatinine &lt; or = 2 md/dL&#xD;
&#xD;
               -  Total bilirubin &lt; or = 1.5 x the upper limit of normal&#xD;
&#xD;
               -  Asparatate aminotransferase (AST) &lt; 3x the upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected allergy to trial product or related products&#xD;
&#xD;
          2. Previous participation in this trial&#xD;
&#xD;
          3. AML classified as FAB M3 (APL, acute promyelocytic leukaemia) or with good prognosis&#xD;
             AML i.e. t(8;21)(q22;q22) or inv(16)(p13q22) or t(16;16)(p13;q22) or their molecular&#xD;
             equivalents&#xD;
&#xD;
          4. Eligibility for allogeneic haematopoietic transplantation&#xD;
&#xD;
          5. The patient is currently receiving, or has within the last 4 weeks received other&#xD;
             investigational anti-leukemic treatment such as cytokine treatment, except&#xD;
             Anti-KIR(1-7F9)&#xD;
&#xD;
          6. The patient has received G-CSF treatment within the last 30 days prior to screening&#xD;
&#xD;
          7. Systemic steroid treatment within the last 4 weeks prior to screening&#xD;
&#xD;
          8. Patient has active autoimmune disease&#xD;
&#xD;
          9. Diagnosis of monoclonal gammopathy&#xD;
&#xD;
         10. Patient has active infectious disease&#xD;
&#xD;
         11. Previous leukaemic CNS involvement&#xD;
&#xD;
         12. Cardiac failure (New York Heart Association [NYHA] grade III-IV)&#xD;
&#xD;
         13. Left ventricular ejection fraction (LVEF) less than 45 % of normal evaluated by&#xD;
             ultrasound or isotopic evaluation&#xD;
&#xD;
         14. Severe neurological/psychiatric disorder&#xD;
&#xD;
         15. HIV or chronic hepatitis infection&#xD;
&#xD;
         16. Clinical evidence of an active second malignancy&#xD;
&#xD;
         17. Mental incapacity, unwillingness or language barriers precluding adequate&#xD;
             understanding or co-operation&#xD;
&#xD;
         18. Any new medical condition that in the opinion of the Investigator disqualifies the&#xD;
             patient for inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert Vey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli Calmettes Marseille France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <state>Marseille Cedex 09</state>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Dupuytren</name>
      <address>
        <city>LIMOGES Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.R.U. de Nantes - Hotel Dieu</name>
      <address>
        <city>NANTES Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud - Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Purpan</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

